Treatment of prostate cancer
US8791094B2 · kind B2 · utility
7Cited by
7References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 5, 2010 |
| Grant date | Jul 29, 2014 |
| Priority date | — |
| Expiry date | Oct 18, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07J43/003
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat androgen receptor mediated diseases or conditions. Such compounds include inhibitors of cytochrome C17α-hydroxylase/C17,20-lyase such as 3-β-Hydroxy-17-(1H-benzimidazol-1-yl)androsta-5,16-diene.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.